Horizon 2020 (2014 - 2020)

Improving low-dose radiation risk appraisal in medicine

Last update: Jun 9, 2020 Last update: Jun 9, 2020

Details

Location:EU 27, Switzerland
EU 27, Switzerland
Grantmaking entity type:Development Institution
Status:Awarded
Budget: EUR 6,000,000
Award ceiling: EUR 6,000,000
Award floor:N/A
Sector:Energy, Health, Research & Innovation
Eligible applicants:Unrestricted / Unspecified
Eligible citizenships:EU 27, Albania, Anguilla, Armeni ...
EU 27, Albania, Anguilla, Armenia, Aruba, Bermuda, Bosnia and Herzegovina, British Virgin Islands, Caribbean Netherlands, Cayman Islands, Falkland Islands, French Polynesia, French Southern Territory, Georgia, Iceland, Israel, Moldova, Montenegro, Montserrat, New Caledonia, North Macedonia, Norway, Pitcairn, Saint Helena, Serbia, St. Pierre and Miquelon, Switzerland, Tunisia, Turkey, Turks and Caicos, Ukraine, Wallis and Futuna
Date posted: Dec 24, 2018

Attachments 1

Associated Awards

Description

Call Updates

Feb 17, 2020 2:20:26 PM

An overview of the evaluation results (flash call info) is now available under the Topic conditions & documents section on the topic page.

Sep 26, 2019 6:33:41 PM

A total of 62 proposals were submitted in response to this call. The number of proposals for topic is shown below:

NFRP-2019-2020-14 (RIA) - 2 proposals

May 15, 2019 12:30:00 AM

The submission session is now available for: NFRP-2019-2020-14(RIA)


Improving low-dose radiation risk appraisal in medicine

ID: NFRP-2019-2020-14

Type of action:RIA Research and Innovation action

Deadline Model: single-stage

Planned opening date: 15 May 2019

Deadline:25 September 2019 17:00:00 Brussels time Forthcoming

Horizon 2020
 
Work programme:   Euratom Work Programme 2019-2020
Work programme year: H2020-2018-2020
 
Call name: Nuclear Fission and Radiation Protection Research  |  Call ID: NFRP-2019-2020See all topics of this call

Topic Description
 
Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, medical applications are the main contributor to the exposure of the European population to ionising radiation. The use of appropriate radioisotopes in nuclear medicine in diagnostic and therapy (theranostics) is progressing. The reinforced risk appraisal of medical exposure will reinforce consideration of benefits. It includes the selection of appropriate radioactive cytostatic compounds and the establishment of adequate controls of their discharges in water streams by selecting short-lived radioisotopes that take into account the protection of workers, carers and comforters, the public and the environment. These progresses will be faster if more certainty about overall detriment is available. Moreover, the medical sector is the best place to keep record of the overall health condition of patients. Thus, using data of patients in the medical sector together with radiation exposure records will improve knowledge. Previous funding efforts have launched collaboration between radiological protection specialists and medical doctors. It deserves further collaboration as results can be used for other exposure situations.

Scope: 

This action should add clarity on detriment from new medical applications of ionising radiation in view of their fast deployment. This should include harmonised patient data collection from different disciplines and treatment approaches in order to enable deduction of the mechanisms leading to health detriment and to enable improved treatment. This should apply due consideration to double causation and peculiar conditions to medical procedures. This action should take into account the gap analysis performed by MELODI, EURADOS and EURAMED, and address the key issue of individual sensitivity and susceptibility to radiation. The proposal should include methods for radiation detriment appraisal with demonstrable shift from the current metrics. It should take due account of previous research that is cross-cutting with health and radiological protection. This data should include data collected from imaging procedures benefiting to the most sensitive, extensive and long lasting followed-up category of patients. It should also include data on most exposed medical staff as well as patients of nuclear medicine, including theranostics. It should also provide recommendations on radiological protection for the development of new applications of radiation in medical care, per category and per procedure. It should involve radiology and therapy equipment manufacturers or their associations, European associations of researchers in this field, organisations having a regulatory mandate for radiation protection research from Member States or EU bodies and universities and hospitals. It should also involve radioisotope developers and suppliers. Proposals in this topic should take into consideration risk communication and the ethics of medical applications.

At least 5% of the total action budget must be dedicated to Education and Training activities for PhD students, postdoctoral researchers and trainees supported through the action (see Conditions for the Call- Eligibility and admissibility conditions).

The Commission considers that proposals requesting a contribution from the Euratom Programme up to EUR 6.0 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:New applications of radiation in medical care will be able to use fast-track approval procedures thanks to the better appraisal of their possible health detriment. This action will improve risk assessment capabilities of the two main sources of radiation exposure of the European population through improved knowledge on internal exposure. In the long term, it will help controlling the discharge of cytostatic compounds in the environment.

 

Want to unlock full information?
Member-only information. Become a member to access this information. Procurement notices from over 850+ sources of tenders and grants published by donors, development banks, foundations, and international financial institutions (IFIs) are available here.
grant Background

About the Funding Agency

Horizon 2020 - is a Framework Programme for Research and Technological Development, and is created by the European Union in order to support and encourage research in the European Research Area (ERA). This is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. The Horizon 2020 programme running from 2014 to 2020 has a €79 billion budget (a 46% increase over FP7).

It is structured around three core pillars:

  • Excellent Science (~€24.4bn)
  • Industrial Leadership (~€17bn)
  • Societal Challenges (~€29.7bn)

Type of projects: mostly grants, no supplies, no works.

In order to see Horizon 2020 opportunities on DevelopmentAid, please click here.

About the Sectors

Energy

Involves the production, transformation, transportation, and distribution of energy from renewable and non-renewable sources.


Key areas:
  • Renewable and non-renewable energy production
  • Energy infrastructure and distribution systems
  • Power generation and energy supply solutions

Health

Covers healthcare services, public health systems, and activities aimed at promoting physical and mental well-being.


Key areas:
  • Healthcare services and facilities
  • Public health and disease prevention
  • Medical equipment, supplies, and services